Humira

AbbVie faces class action lawsuit from New York grocery union over Humira 'patent thicket'
AbbVie faces class action lawsuit from New York grocery union over Humira 'patent thicket'
Fierce Pharma
AbbVie
Humira
patents
Flag link:
2 Things Investors Are Missing About AbbVie
2 Things Investors Are Missing About AbbVie
Motley Fool
AbbVie
ABBV-599
Humira
risankizumab
upadacatinib
Imbruvica
Venclexta
Orilissa
Flag link:
AbbVie’s Humira Remains the Top-Selling Prescription for 2018
AbbVie’s Humira Remains the Top-Selling Prescription for 2018
Biopharma Dive
AbbVie
Humira
prescription data
Flag link:
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
BioSpace
Takeda
Entyvio
AbbVie
Humira
ulcerative colitis
Flag link:
AbbVie and Pfizer return to the top of pharma's TV spending list for February
AbbVie and Pfizer return to the top of pharma's TV spending list for February
Fierce Pharma
AbbVie
Humira
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Fierce Pharma
AbbVie
Boehringer Ingelheim
Humira
biosimilars
Flag link:
Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Forbes
AbbVie
Humira
drug pricing
Senate
pharma executives
Flag link:
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Flag link:
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
AbbVie loses bid to hoard documents in Humira patent fight with Boehringer
Fierce Pharma
Boehringer Ingelheim
AbbVie
biosimilars
Humira
patents
Flag link:
Forget Humira -- Here's What You Need to Know About AbbVie
Forget Humira -- Here's What You Need to Know About AbbVie
Motley Fool
AbbVie
Humira
Upadacitinib
risankizumab
Rick Gonzalez
Flag link:
AbbVie loses $8B in market cap on steeper Humira erosion
AbbVie loses $8B in market cap on steeper Humira erosion
BioCentury
AbbVie
Humira
biosimilars
Flag link:
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
CP Wire
Coherus Biosciences
AbbVie
Humira
CHS-1420
biosimilars
Flag link:
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Coherus Biosciences
AbbVie
Humira
CHS-1420
Flag link:
AbbVie profit misses as Humira faces biosimilar challenge in Europe
AbbVie profit misses as Humira faces biosimilar challenge in Europe
Yahoo/Reuters
AbbVie
earnings
Humira
Flag link:
3 Big Reasons Why AbbVie Isn't Worried About Humira
3 Big Reasons Why AbbVie Isn't Worried About Humira
Yahoo/Motley Fool
AbbVie
Humira
JPMHC 2019
Flag link:
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Reuters
Eli Lilly
psoriatic arthritis
Taltz
AbbVie
Humira
clinical trials
Flag link:
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
Fierce Pharma
AbbVie
biosimilars
Pfizer
Humira
patents
Flag link:
Why Abbvie Is Down 5% in 2018 So Far
Why Abbvie Is Down 5% in 2018 So Far
Motley Fool
AbbVie
Imbruvica
Humira
Orilissa
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:

Pages